Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Misplaced Gut Bacteria Could Change Critical Care Maxims

By HospiMedica International staff writers
Posted on 04 Aug 2016
A new study suggests that gut microbiome disruption may play a key role in sepsis and acute respiratory distress syndrome (ARDS) by infecting the lungs and other tissues.

Researchers at the University of Michigan (Ann Arbor, USA) used genetic tools and bacterial culture techniques to study the lung microbiome in 68 patients with ARDS, and compared them to samples from healthy volunteers. More...
They also examined specimens from a murine model of induced sepsis. They found evidence that the lung microbiome was enriched with gut bacteria, both in the murine model of sepsis and in the humans with established ARDS.

An ecological analysis identified the lower gastrointestinal (GI) tract, rather than the upper respiratory tract, as the likely source community of post-sepsis lung bacteria. In bronchoalveolar lavage fluid from the humans with ARDS, gut-specific bacteria were common and abundant, undetected by culture, and correlated with the intensity of systemic inflammation. Analysis revealed that alveolar tumor necrosis factor (TNF-α), a key mediator of alveolar inflammation in ARDS, was significantly correlated with the altered lung microbiota.

The researchers believe that patients with sepsis and ARDS may actually be trapped in a vicious cycle caused by microbiome dysbiosis; changes in the microbiome lead to inflammation; that inflammation in turn injures delicate lung tissues. The injury and inflammation subsequently allow translocation of bacteria from the gut to the lungs, or alternatively change the microenvironment within the lung to allow microbes present in low levels to multiply. The study was published on July 18, 2016, in Nature Microbiology.

“Our results suggest that in our past attempts to find treatments for sepsis and ARDS, we may have been overlooking a major part of the story,” said lead author critical care physician Robert Dickson, MD. “Virtually all of our attempts to treat these critical illnesses have been aimed at fixing the disordered inflammation and tissue injury we can see in our patients. But our study raises the possibility that this inflammation and injury may actually be downstream consequences of an upstream source: disordered bacterial communities in the gut and lung.”

ARDS is a disease of the alveoli of the lungs that leads to decreased exchange of oxygen and carbon dioxide (CO2). It is associated with several pathologic changes: the release of inflammatory chemicals, breakdown of the cells lining the lung's blood vessels, surfactant loss leading to increased surface tension in the lung, fluid accumulation in the lung, and excessive fibrous connective tissue formation. The condition affects an estimated 2.2 million people worldwide each year, and has a high mortality rate of 20-50%.

Related Links:
University of Michigan



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringes
Prefilled Saline Flush Syringes
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.